To better understand the clinical effectiveness of therapies used in treating relapsed/refractory multiple myeloma (MM) in the real-world clinical practice.
To describe clinical characteristics, treatment & response patterns, and assess outcomes in patients with MF-CTCL treated with Valchlor during the study observation period.
To assess the dosimetric impact on the planning with different treatment protocol, technique and planning system
To compare the efficacy of 2 different treatments in patients with Chronic Phase CML as measured by major molecular response (MMR) rate at 12 months.
To describe the clinical burden, healthcare resource utilization, complications, practice patterns, and therapy strategies in patients treated for PV in academic & community clinical practices within the United States.
Retrospective Studies (Investigator Initiated)
To compare the oncologic outcomes (local control, regional control, distant control, disease-free survival, cause-specific survival, overall survival) and rate of toxicities (frequency of symptoms) for patients diagnosed with a cancer in the chest or female reproductive tract.
To compare the RTOG guidelines for a target volume using anatomical guidelines to a volume outlined via Computed Tomography and the subsequent radiation treatment’s dosage to surrounding tissues.
To compare the oncologic outcomes (local control, regional control, distant control, disease-free survival, cause-specific survival, overall survival) and rate of toxicities (frequency of symptoms) for patients diagnosed with a cancer in the gastrointestinal tract.
To demonstrate the overall survival of subjects receiving a single agent for Chemo-Induced Anemia in Stage IV Non-small Cell Lung Cancer patients.
To assess the efficacy and safety of iron chelation therapy with a single agent compared to placebo in patients with myelodysplastic syndromes (MDS) (low/int-1 risk) and transfusional iron overload.
To describe current treatment patterns in the real-world setting among CLL patients who are initiating treatment with novel therapies including approved oral kinase inhibitors, BCL2 inhibitors, or other approved anti-CLL therapies/regimens as first- or later-line therapy, & explore the associations with baseline patient characteristics, healthcare resource utilization, & clinical outcomes.
To compare the effects of performing a standard lymph node removal versus an extended lymph node removal.